家庭醫(yī)生制度下藥師參與腦卒中患者長(zhǎng)期藥物治療管理模式實(shí)踐及評(píng)價(jià)
中圖分類(lèi)號(hào)R95 文獻(xiàn)標(biāo)志碼A 文章編號(hào) 1001-0408(2025)09-1129-06
DOI 10.6039/j.issn.1001-0408.2025.09.19
ABSTRACTOBJECTIVEToinvestigatetheclinical eficacyof integrating pharmacists intofamily healthteams(FHTs)for long-termmedicationtherapeuticalmanagement (MTM)in stroke patients,andempiricallyevaluate theservice model.METHODS A pharmacistteam,jointlyestablishedbyclinicalandcommunitypharmacistsfromtheAfiliated Suzhou Hospitalof Nanjing MedicalUniversty(hereinaftereferrdtoas“ourhospital"),developedapharmacist-supportedMMmodelintegrateditoFHs. Usingaprospectiverandomizedcontrolleddesign,17Ostrokepatientsdischargedfromourhospital(July202-December 2023)
and enrolled in FHTs at Suzhou Runda Community Hospital wererandomlydivided into trial group(88 cases)and control group (82 cases) according to random number table. The control group received routine FHTs care(without pharmacist involvement in the team collaboration),while the trial group received 12-monthMTM services supportedbypharmacistsvia
aninformationplatform.Theseservicesspecificallyincludedinnovativeinterventionssuchaspersonalizedmedicationregimen optimization basedonthe MTM framework,dynamic medicationadherencemanagement,medication safety monitoring,a home medicationasessment system,and distinctiveserviceoferings.Outcomesof the2grousp werecomparedbeforeandafter intervention,involvingmedicationaderence(aderencerate,aherencescore),omplianceratesforstrokerecurenceriskfactors [blood pressure,low-densitylipoproteincholesterol(LDL-C)],andincidenceofadversedrugreactions(ADR).RESULTSAfter 12months,thetrialgroupexhibitedsignificantlyhighermedicationadherencerates,mprovedadherencescores,highrcompliance rates for blood pressure and LDL-C targets compared to the control group ? P<0 . 0 5 ). The incidence of ADR in the trial group 0 4 . 5 5 % )was significantly lower than that in the control group ( 8 . 1 1 % ),though the difference was not statistically significant( P > 0.05).CONCLUSIONS Pharmacist involvement inFHTs todeliver MTMservices significantlyenhances medicationadherence and optimizesriskfactorforstrokerecurrence,oferingpracticalevidenceforadvancingpharmaceuticalcareinchronicdisease management under the family doctor system.
KEYWORDSfamilydoctorsystem;clinicalpharmacist;communitypharmacist;stroke;pharmaceuticalcare;medicatior therapeutical management;medication compliance
腦卒中是危害我國(guó)人民健康的首要?dú)⑹?,具有高發(fā)病率、高死亡率、高致殘率以及高復(fù)發(fā)率的特點(diǎn)。(剩余9884字)
- 《骨質(zhì)疏松癥臨床治療生物制劑循...
- 中美日藥品說(shuō)明書(shū)適老化管理的對(duì)...
- 我國(guó)航空醫(yī)療救援藥品使用現(xiàn)狀分...
- 基于定性、定量及化學(xué)模式識(shí)別分...
- 溫脾通絡(luò)開(kāi)竅方抑制AD小鼠神經(jīng)...
- 鉤苞大丁草的HPLC指紋圖譜建...
- 雙術(shù)湯對(duì)大鼠的安全性及改善消化...
- 指紋圖譜結(jié)合含量測(cè)定分析黃芪悶...
- 不同基原積實(shí)的多組分含量測(cè)定及...
- 匹妥布替尼在大鼠體內(nèi)的代謝產(chǎn)物...
- 檸檬苦素對(duì)妊娠期糖尿病大鼠腎臟...
- 司美格魯肽對(duì)比卡格列凈治療二甲...
- 兒童患者萬(wàn)古霉素穩(wěn)態(tài)血藥濃度谷...
- 基于病例報(bào)告文獻(xiàn)的妊娠期使用磺...
- 難治性化療所致惡心嘔吐的列線(xiàn)圖...
- 不同劑型短效rhGH治療矮小癥...
- 我國(guó)醫(yī)療機(jī)構(gòu)藥學(xué)監(jiān)護(hù)開(kāi)展現(xiàn)狀調(diào)...
- 利用ECHO模型評(píng)價(jià)藥學(xué)質(zhì)控對(duì)...
- 家庭醫(yī)生制度下藥師參與腦卒中患...
- 羅特西普治療骨髓增生異常綜合征...
- 替爾泊肽用于2型糖尿病和長(zhǎng)期體...
- 姜黃素抗抑郁作用機(jī)制的研究進(jìn)展...